Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
2.970
0.00 (0.00%)
At close: Sep 5, 2025, 4:00 PM
3.010
+0.040 (1.35%)
After-hours: Sep 5, 2025, 5:20 PM EDT
Anixa Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
95.67M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Oct 31, 2024 | - | - | - |
Oct 31, 2023 | 210.00K | - | - |
Oct 31, 2022 | - | - | - |
Oct 31, 2021 | 512.00K | - | - |
Oct 31, 2020 | - | - | - |
Oct 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Oct 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Oct 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Oct 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Oct 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ANIX News
- 5 days ago - Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 13 days ago - Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 18 days ago - Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology - PRNewsWire
- 20 days ago - Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial - PRNewsWire
- 26 days ago - Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology - PRNewsWire
- 4 weeks ago - Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference - PRNewsWire
- 4 weeks ago - Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial - PRNewsWire
- 5 weeks ago - Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology - PRNewsWire